• Sunshine Biopharma reset the exercise price on its outstanding Series B Warrants to $1.22 following recent at-the-market share sales.
• The revised exercise price remains subject to further adjustment under the Series B Warrant terms.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sunshine Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-005899), on August 03, 2026, and is solely responsible for the information contained therein.